Gsk
Rivals turn partners for COVID-19 vaccine challenge
The latest tie-up involves US giant Merck which agreed to help produce the potentially key one-shot vaccine developed by Johnson & Johnson.
-
Sanofi, GSK COVID vaccine delayed until end of 2021
The announcement is a huge setback in efforts to fight the pandemic, which first emerged in China last December and has killed over 1.5 million people worldwide.
-
Sixth trial of potential Chinese COVID-19 shot begins with GSK, Dynavax mix
There are no approved vaccines or treatments for the illness caused by the new coronavirus, but about a dozen vaccines are being trialled globally.
-
GSK in Epping closes doors after several workers test positive for COVID-19
The Department of Employment and Labour has also issued GlaxoSmithKline with a prohibition notice following an inspection this week.
-
Big pharma leaves big gaps: Drugmakers urged to do more for poor
Research into urgently needed medicines for the developing world now relies on just a handful of companies, creating a fragile ecosystem where cutbacks by one player could have a significant impact on future supplies.
-
Orchard raises $150m to expand after GSK gene therapy deal
The new financing comes four months after its acquisition of a portfolio of GlaxoSmithKline rare disease medicines, including the gene therapy Strimvelis.
-
GSK and Gilead go head to head as HIV drugs enter new phase
The stakes are high for the two leaders in the $27-billion-a-year HIV market, with shares of around 53 and 22% respectively, according to industry data.
-
GSK launches big study to test new HIV prevention drug
The study aims to enrol 4,500 men who have sex with men, and transgender women who have sex with men, at 40 sites across the world.
-
GlaxoSmithKline beats forecasts as HIV drugs, flu vaccines shine
Third quarter sales, in sterling terms, rose 9 percent to £6.13 billion, although profits were still down.
-
GSK's hunt for Aids cure accelerates
The drugmaker will invest $20 million to help fund the work for an initial five years.
-
GSK raises $853m by halving stake in Aspen
GSKs CEO said the disposal would help give his company flexibility to invest in new opportunities.
